Functional defects of Tr1 cells have been described in MS patients, using IL-10 secretion ex vivo as indirect assessment of their suppressive function (121, 122), and during several tolerization trials in MS patients increased levels of Tr1 cells have been reported (123–125). Here, IL10 is linked to myeloid sarcoma.